Brian Culley
Algemeen Directeur bij LINEAGE CELL THERAPEUTICS, INC.
Vermogen: 171 875 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michael Mulroy | M | 58 | 10 jaar | |
Don Bailey | M | 78 | 8 jaar | |
George Samuel | M | 43 | 3 jaar | |
Neal Bradsher | M | 58 | 15 jaar | |
Angus Russell | M | 68 | 10 jaar | |
Anula Kusum Jayasuriya | M | 67 | 3 jaar | |
Deborah Andrews | F | 66 | 10 jaar | |
Dipti Amin | M | 60 | 3 jaar | |
Derek Kelaita | M | - | 5 jaar | |
Jill Howe | F | 48 | 2 jaar | |
Munish Mehra | M | - | - | |
Timothy Duane | M | - |
University of California, Berkeley
| 25 jaar |
Frank Lanza | M | 62 | 8 jaar | |
Gary Hogge | M | 56 | 6 jaar | |
Daniel M. Kammen | M | 62 |
University of California, Berkeley
| 25 jaar |
Michael Franklin | M | - |
University of California, Berkeley
| 25 jaar |
Ioana C. Hone | F | - | - | |
Ronald Kurtz | M | 61 |
University of California, Berkeley
| 24 jaar |
Jennifer Bahr-Davidson | M | - | 14 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Patrick Keran | M | 52 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 jaar |
Brandi Roberts | F | 50 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 jaar |
Alfred Kingsley | M | 81 | 15 jaar | |
Evan Levine | M | 59 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 jaar |
Adi Mohanty | M | 57 | 4 jaar | |
Stephana Patton | M | 54 | 2 jaar | |
Judith Segall | F | 70 | 29 jaar | |
Steve Cartt | M | 61 | 3 jaar | |
S Chu Schubert | M | 51 |
University of California, Berkeley
| 8 jaar |
Shana C. Hood | F | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Richard Towne LeBuhn | M | 59 | 5 jaar | |
Michael West | M | 71 | 16 jaar | |
Joel Drescher | M | - |
University of California, Berkeley
| 5 jaar |
Nickhil Jakatdar | M | - |
University of California, Berkeley
| 4 jaar |
Jen L. Neumann | F | - |
University of California, Berkeley
| 4 jaar |
Bambang Susantono | M | 60 |
University of California, Berkeley
| 3 jaar |
Yi Ma | M | 51 |
University of California, Berkeley
| 4 jaar |
Chase Leavitt | M | 42 | 2 jaar | |
Kevin Cook | M | 53 | 1 jaar | |
Peter Greenleaf | M | 54 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Daniel K. Nomura | M | - |
University of California, Berkeley
| 9 jaar |
Laura Parada | M | - |
University of California, Berkeley
| 5 jaar |
Ki-Ha Lee | M | - |
University of California, Berkeley
| 5 jaar |
Howard I. Scher | M | 72 | 3 jaar | |
Cavan Redmond | M | 63 | 1 jaar | |
Andy Arno | M | 64 | 5 jaar | |
Nat Ricciardi | M | 75 | 5 jaar | |
Howard C. Dittrich | M | 71 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 3 jaar |
David Ramsay | M | 59 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 jaar |
Russell Skibsted | M | 65 | 4 jaar | |
Ted Love | M | 65 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 1 jaar |
Stephen Farrell | M | 59 | 7 jaar | |
Gregory P. Hanson | M | 77 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 2 jaar |
Jack Lief | M | 78 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 jaar |
Carrie E. Carlander McQueen | F | 53 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Eric Rowinsky | M | 67 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Lewis J. Shuster | M | 68 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 5 jaar |
Michael Surowiecki | M | - |
University of California, Berkeley
| 2 jaar |
Ron Roe | M | 47 |
University of California, Berkeley
| 4 jaar |
Jonathan Bradley Feske | M | - |
University of California, Berkeley
| 4 jaar |
Wai Wen | M | - |
University of California, Berkeley
| 4 jaar |
Hui Zhang | M | 52 |
University of California, Berkeley
| 3 jaar |
Tak Wai Wong | M | 47 |
University of California, Berkeley
| 4 jaar |
Lorna L. Tanner | F | - |
University of California, Berkeley
| 4 jaar |
Esina Alic | F | - |
University of California, Berkeley
| 2 jaar |
Kristine Diamond | F | 56 |
University of California, Berkeley
| 2 jaar |
Daniel Fetters | M | 50 |
University of California, Berkeley
| 4 jaar |
Irena Blind | F | - |
University of California, Berkeley
| 4 jaar |
Ann Bordetsky | F | - |
University of California, Berkeley
| 4 jaar |
Stan Miroshnik | M | - |
University of California, Berkeley
| 4 jaar |
Albert Wang | M | - |
University of California, Berkeley
| 4 jaar |
Abu Ramin | M | - |
University of California, Berkeley
| 4 jaar |
Gabe Turner | M | 42 |
University of California, Berkeley
| 4 jaar |
Mike Boggs | M | - |
University of California, Berkeley
| 4 jaar |
Brian D. Martin | M | - |
University of California, Berkeley
| 4 jaar |
Amit Mehrotra | M | - |
University of California, Berkeley
| 3 jaar |
Nathan Brostrom | M | - |
University of California, Berkeley
| 12 jaar |
B. C. Brant | M | - |
University of California, Berkeley
| 1 jaar |
Vitaly Bezrodnykh | M | - |
University of California, Berkeley
| 2 jaar |
Jeremy P. Kath | M | - |
University of California, Berkeley
| 2 jaar |
Jonathan Mi | M | - |
University of California, Berkeley
| 4 jaar |
Jay Traeger | M | - |
University of California, Berkeley
| 4 jaar |
Julie Liu | F | - |
University of California, Berkeley
| 2 jaar |
Linda Contreras | F | - |
University of California, Berkeley
| 4 jaar |
Karen Madden | F | - |
University of California, Berkeley
| 2 jaar |
Todd Ammons | M | - |
University of California, Berkeley
| 4 jaar |
Carol Tecla Christ | M | 79 |
University of California, Berkeley
| 6 jaar |
Adrienne Hudspeth | F | - |
University of California, Berkeley
| 4 jaar |
Jon David McAuliffe | M | - |
University of California, Berkeley
| 5 jaar |
Dominic Ang | M | 46 |
University of California, Berkeley
| 4 jaar |
Kanyu Cao | M | - |
University of California, Berkeley
| 3 jaar |
Ken M. Wisdom | M | - |
University of California, Berkeley
| 2 jaar |
Chris J. McBee | M | - |
University of California, Berkeley
| 2 jaar |
Yi Shan Li | M | 59 |
University of California, Berkeley
| 2 jaar |
Peter Smith | M | - |
University of California, Berkeley
| 3 jaar |
Timothy Kutzkey | M | 49 |
University of California, Berkeley
| 6 jaar |
Jon S. Orban | M | 55 |
University of California, Berkeley
| 4 jaar |
Paras P. Maniar | M | - |
University of California, Berkeley
| 4 jaar |
Seth D. Greenstein | M | - |
University of California, Berkeley
| 5 jaar |
Marcos Stefan Kulka Kuperman | M | - |
University of California, Berkeley
| 2 jaar |
Margo Diamond | M | - |
University of California, Berkeley
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Brian Culley
- Persoonlijk netwerk